A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA With Costimulatory Molecules

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0183
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Targeting DNGR-1 (CLEC9A) With Antibody/Muc1 Peptide Conjugates as a Vaccine for Carcinomas

European Journal of Immunology
AllergyImmunology
2014English

Safety and Immunogenicity of a mRNA-based Chikungunya Vaccine in a Phase 1 Dose-Ranging Trial

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Treatment of Advanced Pancreatic Carcinoma With 90y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

Clinical Cancer Research
Cancer ResearchOncology
2011English

OPTIMA: A Phase II Dose and Volume De-Escalation Trial for Human Papillomavirus-Positive Oropharyngeal Cancer

Annals of Oncology
MedicineOncologyHematology
2019English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

First-In-Human Phase 1 Trial of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine

Retrovirology
VirologyInfectious Diseases
2012English

A Phase I Dose-Escalation Trial of Stereotactic Body Radiotherapy Using 4 Fractions for Patients With Localized Prostate Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

Clinical Cancer Research
Cancer ResearchOncology
2017English

A Phase I/Ii Seamless Dose Escalation/Expansion With Adaptive Randomization Scheme (SEARS)

Clinical Trials
MedicinePharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy